Stocks and Investing Stocks and Investing
Wed, April 12, 2023

Nigel Dally Maintained (ARQT) at Buy with Decreased Target to $47 on, Apr 12th, 2023


Published on 2024-10-28 02:42:24 - WOPRAI, Nigel Dally
  Print publication without navigation


Nigel Dally of Morgan Stanley, Maintained "Arcutis Biotherapeutics, Inc." (ARQT) at Buy with Decreased Target from $50 to $47 on, Apr 12th, 2023.

Nigel has made no other calls on ARQT in the last 4 months.



There are 4 other peers that have a rating on ARQT. Out of the 4 peers that are also analyzing ARQT, 0 agree with Nigel's Rating of Hold.



These are the ratings of the 4 analyists that currently disagree with Nigel


  • Uy Ear of "Mizuho" Reiterated at Strong Buy and Held Target at $61 on, Tuesday, April 11th, 2023
  • Gregory Fraser of "Truist Securities" Maintained at Strong Buy with Decreased Target to $45 on, Wednesday, March 29th, 2023
  • Serge Belanger of "Needham" Maintained at Strong Buy with Decreased Target to $24 on, Thursday, March 16th, 2023
  • Vikram Purohit of "Morgan Stanley" Maintained at Buy with Decreased Target to $50 on, Wednesday, March 1st, 2023
Contributing Sources